Clinical potential of nintedanib for the second-line treatment of advanced non-small-cell lung cancer: current evidence

References

• SiegelRNaishadhamDJemalACancer statistics, 2013CA Cancer J Clin2013631113023335087
   PubMed Web of Science ®Google Scholar
• HanahanDFolkmanJPatterns and emerging mechanisms of the angiogenic switch during tumorigenesisCell19968633533648756718
   PubMed Web of Science ®Google Scholar
• KerbelRSAntiangiogenic therapy: a universal chemosensitization strategy for cancer?Science200631257771171117516728631
   PubMed Web of Science ®Google Scholar
• KreuterMKropffMFischaleckAPrognostic relevance of angiogenesis in stage III NSCLC receiving multimodality treatmentEur Respir J20093361383138819213790
   PubMed Web of Science ®Google Scholar
• MeertAPPaesmansMMartinBThe role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysisBr J Cancer200287769470112232748
   PubMed Web of Science ®Google Scholar
• WeidnerNIntratumor microvessel density as a prognostic factor in cancerAm J Pathol199514719197541613
   PubMed Web of Science ®Google Scholar
• JainRKNormalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapyNat Med20017998798911533692
   PubMed Web of Science ®Google Scholar
• GiacconeGThe potential of antiangiogenic therapy in non-small cell lung cancerClin Cancer Res20071371961197017404076
   PubMed Web of Science ®Google Scholar
• CarmelietPVEGF as a key mediator of angiogenesis in cancerOncology200569Suppl 341016301830
   PubMed Web of Science ®Google Scholar
• BremnesRMCampsCSireraRAngiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and bloodLung Cancer200651214315816360975
   PubMed Web of Science ®Google Scholar
• ItoHOshitaFKamedaYExpression of vascular endothelial growth factor and basic fibroblast growth factor in small adenocarcinomasOncol Rep20029111912311748468
   PubMed Web of Science ®Google Scholar
• VolmMKoomagiRMatternJPD-ECGF, bFGF, and VEGF expression in non-small cell lung carcinomas and their association with lymph node metastasisAnticancer Res1999191B65165510216471
   PubMed Web of Science ®Google Scholar
• FaivreSDjelloulSRaymondENew paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitorsSemin Oncol200633440742016890796
   PubMed Web of Science ®Google Scholar
• CaoYCaoRHedlundEMRegulation of tumor angiogenesis and metastasis by FGF and PDGF signaling pathwaysJ Mol Med (Berl)200886778578918392794
   PubMed Web of Science ®Google Scholar
• ErberRThurnherAKatsenADCombined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanismsFASEB J200418233834014657001
   PubMed Web of Science ®Google Scholar
• ShihAHHollandECPlatelet-derived growth factor (PDGF) and glial tumorigenesisCancer Lett2006232213914716139423
   PubMed Web of Science ®Google Scholar
• BeenkenAMohammadiMThe FGF family: biology, pathophysiology and therapyNat Rev Drug Discov20098323525319247306
   PubMed Web of Science ®Google Scholar
• LimSMKimHRShimHSSooRAChoBCRole of FGF receptors as an emerging therapeutic target in lung squamous cell carcinomaFuture Oncol20139337738623469973
   PubMed Web of Science ®Google Scholar
• PrestaMDell’EraPMitolaSMoroniERoncaRRusnatiMFibroblast growth factor/fibroblast growth factor receptor system in angiogenesisCytokine Growth Factor Rev200516215917815863032
   PubMed Web of Science ®Google Scholar
• RosenLSClinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockersCancer Control20029Suppl 2364411965229
   PubMedGoogle Scholar
• BergersGSongSMeyer-MorseNBergslandEHanahanDBenefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitorsJ Clin Invest200311191287129512727920
   PubMed Web of Science ®Google Scholar
• CasanovasOHicklinDJBergersGHanahanDDrug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumorsCancer Cell20058429930916226705
   PubMed Web of Science ®Google Scholar
• FerraraNHillanKJGerberHPNovotnyWDiscovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNat Rev Drug Discov20043539140015136787
   PubMed Web of Science ®Google Scholar
• SandlerAGrayRPerryMCPaclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancerN Engl J Med2006355242542255017167137
   PubMed Web of Science ®Google Scholar
• HerbstRSToxicities of antiangiogenic therapy in non-small-cell lung cancerClin Lung Cancer20068Suppl 1S23S3017239287
   PubMed Web of Science ®Google Scholar
• ScagliottiGNovelloSvon PawelJPhase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancerJ Clin Oncol201028111835184220212250
   PubMed Web of Science ®Google Scholar
• ReckMvon PawelJZatloukalPPhase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAilJ Clin Oncol20092781227123419188680
   PubMed Web of Science ®Google Scholar
• ReckMvon PawelJZatloukalPOverall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)Ann Oncol20102191804180920150572
   PubMed Web of Science ®Google Scholar
• GaronEBCiuleanuTEArrietaORamucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trialLancet Epub622014
   Web of Science ®Google Scholar
• PerolMCiuleanuTEArrietaOREVEL: a randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line treatment of stage IV non-small cell lung cancer (NSCLC) following disease progression after one prior platinum-based therapyJ Clin Oncol201432Suppl 5LBA8006
   Google Scholar
• WilhelmSMCarterCTangLBAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesisCancer Res200464197099710915466206
   PubMed Web of Science ®Google Scholar
• Paz-AresLGBiesmaBHeigenerDPhase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancerJ Clin Oncol201230253084309222851564
   PubMed Web of Science ®Google Scholar
• BlumenscheinGRJrSaintignyPLiuSComprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trialClin Cancer Res201319246967697524166906
   PubMed Web of Science ®Google Scholar
• Paz-AresLHirshVZhangLMonotherapy administration of sorafenib in patients with non-small cell lung cancer: phase III, randomized, double-blind, placebo-controlled MISSION trialAnn Oncol201223Suppl 9LBA33
   Google Scholar
• MokTSKPaz-AresLWuYLAssociation between tumor EGFR and KRAS mutation status and clinical outcomes in NSCLC patients randomized to sorafenib plus best supportive care (BSC) or BSC alone: subanalysis of the phase III MISSION trialAnn Oncol201223Suppl 9LBA9
   Google Scholar
• SocinskiMANovelloSBrahmerJRMulticenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancerJ Clin Oncol200826465065618235126
   PubMed Web of Science ®Google Scholar
• NovelloSScagliottiGVRosellRPhase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancerBr J Cancer200910191543154819826424
   PubMed Web of Science ®Google Scholar
• NataleRBThongprasertSGrecoFAPhase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancerJ Clin Oncol20112981059106621282542
   PubMed Web of Science ®Google Scholar
• de BoerRHArrietaOYangCHVandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trialJ Clin Oncol20112981067107421282537
   PubMed Web of Science ®Google Scholar
• HerbstRSSunYEberhardtWEVandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC):a double-blind, randomised, phase 3 trialLancet Oncol201011761962620570559
   PubMed Web of Science ®Google Scholar
• LeeJSHirshVParkKVandetanib versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR)J Clin Oncol201230101114112122370318
   PubMed Web of Science ®Google Scholar
• QiWXTangLNHeANShenZYaoYThe role of vandetanib in the second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of four randomized controlled trialsLung2011189643744321986852
   PubMed Web of Science ®Google Scholar
• HilbergFRothGJKrssakMBIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacyCancer Res200868124774478218559524
   PubMed Web of Science ®Google Scholar
• RothGJHeckelAColbatzkyFDesign, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120)J Med Chem200952144466448019522465
   PubMed Web of Science ®Google Scholar
• XiangQFWangFSuXDEffect of BIBF 1120 on reversal of ABCB1-mediated multidrug resistanceCell Oncol (Dordr)2011341334421290212
   PubMed Web of Science ®Google Scholar
• MrossKStefanicMGmehlingDPhase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumorsClin Cancer Res201016131131920028771
   PubMed Web of Science ®Google Scholar
• OkamotoIKanedaHSatohTPhase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumorsMol Cancer Ther20109102825283320688946
   PubMed Web of Science ®Google Scholar
• EllisPMKaiserRZhaoYStopferPGyorffySHannaNPhase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patientsClin Cancer Res201016102881288920460487
   PubMed Web of Science ®Google Scholar
• du BoisAHuoberJStopferPA phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignanciesAnn Oncol201021237037519889612
   PubMed Web of Science ®Google Scholar
• DoebeleRCConklingPTraynorAMA phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancerAnn Oncol20122382094210222345119
   PubMed Web of Science ®Google Scholar
• ReckMKaiserREschbachCA phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancerAnn Oncol20112261374138121212157
   PubMed Web of Science ®Google Scholar
• ReckMKaiserRMellemgaardADocetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trialLancet Oncol201415214315524411639
   PubMed Web of Science ®Google Scholar
• ShepherdFARodrigues PereiraJCiuleanuTErlotinib in previously treated non-small-cell lung cancerN Engl J Med2005353212313216014882
   PubMed Web of Science ®Google Scholar
• ShepherdFADanceyJRamlauRProspective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapyJ Clin Oncol200018102095210310811675
   PubMed Web of Science ®Google Scholar
• HannaNHKaiserRSullivanRNLume-lung 2: a multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapyJ Clin Oncol201331Suppl8034
   Google Scholar
• BergersGHanahanDModes of resistance to anti-angiogenic therapyNat Rev Cancer20088859260318650835
   PubMed Web of Science ®Google Scholar